US equities
|
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
SNDK
$1,719.99
▲+0.00%
NVDA
$233.95
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
WDC
$415.29
▲+0.00%
MSTR
$160.01
▲+0.00%
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
SNDK
$1,719.99
▲+0.00%
NVDA
$233.95
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
WDC
$415.29
▲+0.00%
MSTR
$160.01
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Liquidia Corporation
< Previous
1
2
Next >
Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics
May 12, 2025
From
Liquidia Corporation
Via
GlobeNewswire
Tickers
LQDA
Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 08, 2025
From
Liquidia Corporation
Via
GlobeNewswire
Tickers
LQDA
Liquidia Corporation to Present at BofA Securities 2025 Health Care Conference
May 06, 2025
From
Liquidia Corporation
Via
GlobeNewswire
Tickers
LQDA
District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia
May 02, 2025
From
Liquidia Corporation
Via
GlobeNewswire
Tickers
LQDA
Liquidia Corporation to Report First Quarter 2025 Financial Results on May 8, 2025
May 01, 2025
From
Liquidia Corporation
Via
GlobeNewswire
Tickers
LQDA
UPDATE – Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference
April 01, 2025
From
Liquidia Corporation
Via
GlobeNewswire
Tickers
LQDA
Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference
April 01, 2025
From
Liquidia Corporation
Via
GlobeNewswire
Tickers
LQDA
Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA™ (treprostinil) Inhalation Powder
March 28, 2025
From
Liquidia Corporation
Via
GlobeNewswire
Tickers
LQDA
Liquidia Announces Poster Presentations at the American Thoracic Society (ATS) 2025 International Conference
March 27, 2025
From
Liquidia Corporation
Via
GlobeNewswire
Tickers
LQDA
Liquidia Corporation Reports Full Year 2024 Financial Results and Provides Corporate Update
March 19, 2025
From
Liquidia Corporation
Via
GlobeNewswire
Tickers
LQDA
Liquidia Corporation Strengthens Financial Position by Amending HealthCare Royalty Agreement to Incrementally Add Up to $100 Million
March 18, 2025
From
Liquidia Corporation
Via
GlobeNewswire
Tickers
LQDA
Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025
March 12, 2025
From
Liquidia Corporation
Via
GlobeNewswire
Tickers
LQDA
Liquidia Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference
January 08, 2025
From
Liquidia Corporation
Via
GlobeNewswire
Tickers
LQDA
Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 13, 2024
From
Liquidia Corporation
Via
GlobeNewswire
Tickers
LQDA
Liquidia to Present at the Stifel 2024 Healthcare Conference
November 12, 2024
From
Liquidia Corporation
Via
GlobeNewswire
Tickers
LQDA
Liquidia Corporation to Report Third Quarter 2024 Financial Results on November 13, 2024
November 06, 2024
From
Liquidia Corporation
Via
GlobeNewswire
Tickers
LQDA
Liquidia Corporation to Report Third Quarter 2024 Financial Results on November 11, 2024
November 04, 2024
From
Liquidia Corporation
Via
GlobeNewswire
Tickers
LQDA
United States Supreme Court Declines to Review Rulings that Invalidate United Therapeutics’ Patent
October 07, 2024
From
Liquidia Corporation
Via
GlobeNewswire
Tickers
LQDA
Liquidia and Pharmosa Biopharm Expand Collaboration to Develop Sustained Release Inhaled Treprostinil (L606)
October 02, 2024
From
Liquidia Corporation
Via
GlobeNewswire
Tickers
LQDA
Liquidia Announces Poster Presentation and Medical Theater at the CHEST 2024 Annual Meeting
September 30, 2024
From
Liquidia Corporation
Via
GlobeNewswire
Tickers
LQDA
Court Finds United Therapeutics’ Interference with Launch of Generic Treprostinil Injection Caused Losses of More Than $137 Million
September 16, 2024
From
Liquidia Corporation
Via
GlobeNewswire
Tickers
LQDA
Liquidia Corporation Announces Raise of $67.5 Million from New Common Stock Financings and $32.5 Million Advance from HealthCare Royalty Under Current Financing Agreement
September 11, 2024
From
Liquidia Corporation
Via
GlobeNewswire
Tickers
LQDA
Liquidia to Present at Upcoming Investor Conferences
August 28, 2024
From
Liquidia Corporation
Via
GlobeNewswire
Tickers
LQDA
Liquidia Files Litigation to Challenge Regulatory Exclusivity Blocking Access to YUTREPIA™ (treprostinil) inhalation powder for Patients Suffering with PAH and PH-ILD
August 22, 2024
From
Liquidia Corporation
Via
GlobeNewswire
Tickers
LQDA
U.S. FDA Grants Tentative Approval of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
August 19, 2024
From
Liquidia Corporation
Via
GlobeNewswire
Tickers
LQDA
Liquidia Announces Poster Presentations at the PHA 2024 International PH Conference and Scientific Sessions
August 16, 2024
From
Liquidia Corporation
Via
GlobeNewswire
Tickers
LQDA
Liquidia Corporation Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 07, 2024
From
Liquidia Corporation
Via
GlobeNewswire
Tickers
LQDA
Liquidia Corporation to Report Second Quarter 2024 Financial Results on August 7, 2024
July 31, 2024
From
Liquidia Corporation
Via
GlobeNewswire
Tickers
LQDA
Liquidia Announces Poster Presentations at the 7th World Symposia on Pulmonary Hypertension (WSPH)
June 18, 2024
From
Liquidia Corporation
Via
GlobeNewswire
Tickers
LQDA
District Court Issues Favorable Ruling and Denies United Therapeutics’ Request to Block YUTREPIA™ Launch
June 03, 2024
From
Liquidia Corporation
Via
GlobeNewswire
Tickers
LQDA
< Previous
1
2
Next >
